




Sheet 1 of 3 <div style="position: absolute; top: 0; right: 0; text-align: center;">  </div>							
FORM PTO 1449 (modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) <i>(Use several sheets if necessary)</i> Date Submitted to PTO: October 23, 2006				ATTY DOCKET NO. 2006_1150A		SERIAL NO. 10/586,499	
				APPLICANT Kyogo ITOH et al.			
				FILING DATE July 20, 2006		GROUP	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	AB						
	AC						
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)							
/RL/	AD	T. Yamamoto et al., "Similarity of protein encoded by the human <i>c-erb-B-2</i> gene to epidermal growth factor receptor", <i>Nature</i> , Vol. 319, pp. 230-234, January 16, 1986.					
	AE	L. Coussens et al., "Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with <i>neu</i> oncogene", <i>Science</i> , Vol. 230, pp. 1132-1139, December 1985.					
	AF	D. S. Salomon et al., "Epidermal growth factor-related peptides and their receptors in human malignancies", <i>Critical Reviews in Oncology/Hematology</i> , Vol. 19, pp. 183-232, 1995.					
	AG	V. A. Miller et al., "Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer", <i>Journal of Clinical Oncology</i> , Vol. 21, No. 11, pp. 2094-2100, June 1, 2003.					
	AH	M. Fukuoka et al., "Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer", <i>Journal of Clinical Oncology</i> , Vol. 21, No. 12, pp. 2237-2246, June 15, 2003.					
	AI	G. E. Peoples et al., "Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide", <i>Proc. Natl. Acad. Sci.</i> , Vol. 92, pp. 432-436, January 1995.					
	AJ	B. Fisk et al., "Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines", <i>J. Exp. Med.</i> , Vol. 181, pp. 2109-2117, June 1995.					
	AK	I. Kawashima et al., "Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary <i>in vitro</i> immunization with peptide-pulsed dendritic cells", <i>Cancer Research</i> , Vol. 59, pp. 431-435, January 15, 1999.					
↓	AL	T. Okugawa et al., "A novel human HER2-derived peptide homologous to the mouse K ^d -restricted tumor rejection antigen can induce HLA-A24-restricted cytotoxic T lymphocytes in ovarian cancer patients and healthy individuals", <i>Eur. J. Immunol.</i> , Vol. 30, pp. 3338-3346, 2000.					
EXAMINER				/Robert Landsman/		DATE CONSIDERED	
						11/15/2008	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 2 of 3		INFORMATION DISCLOSURE STATEMENT					
FORM PTO 1449 (modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary) Date Submitted to PTO: October 23, 2006		ATTY DOCKET NO. 2006_1150A		SERIAL NO. 10/586,499			
		APPLICANT Kyogo ITOH et al.					
		FILING DATE July 20, 2006			GROUP		
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	BB						
	BC						
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)							
/RL/	BD	M. Noguchi et al., "Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination", The Prostate, Vol. 57, pp. 80-92, 2003.					
	BE	Y. Sato et al., "Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide", Cancer Science, Vol. 94, No. 9, pp. 802-808, September 2003.					
	BF	T. Mine et al., "Immunological evaluation of CTL precursor-oriented vaccines for advanced lung cancer patients", Cancer Sci., Vol. 94, No. 6, pp. 548-556, June 2003.					
	BG	M. H. Parkar et al., "Expression of growth-factor receptors in normal and regenerating human periodontal cells", Archives of Oral Biology, Vol. 46, pp. 275-284, 2001.					
	BH	M. L. Disis et al., "High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer", Journal of Clinical Oncology, Vol. 15, No. 11, pp. 3363-3367, November 1997.					
	BI	E. Jager et al., "Induction of primary NY-ESO-1 immunity: CD8 + T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1 + cancers", Proc. Natl. Acad. Sci., Vol. 97, No. 22, pp. 12198-12203, October 24, 2000.					
	BJ	S. Ohkouchi et al., "Non-mutated tumor-rejection antigen peptides elicit type-I allergy in the majority of healthy individuals", Tissue Antigens, Vol. 59, pp. 259-272, 2002.					
	BK	N. Kawamoto et al., "IgG reactive to CTL-directed epitopes of self-antigens is either lacking or unbalanced in atopic dermatitis patients", Tissue Antigens, Vol. 61, pp. 352-361, 2003.					
↓	BL	T. Imanishi et al., "Allele and haplotype frequencies for HLA and complement loci in various ethnic groups", In: Proceedings of the Eleventh International Histocompatibility Workshop and Conference, pp. 1065-1220, Oxford University Press, Oxford, United Kingdom, 1992.					
EXAMINER /Robert Landsman/				DATE CONSIDERED 11/15/2008			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 3 of 3 FORM PTO 1449 (modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary) Date Submitted to PTO: October 23, 2006								<div style="text-align: center;">  </div> INFORMATION DISCLOSURE STATEMENT															
				ATTY DOCKET NO. 2006_1150A				SERIAL NO. 10/586,499															
								APPLICANT Kyogo ITOH et al.															
								FILING DATE July 20, 2006				GROUP											
U.S. PATENT DOCUMENTS																							
*EXAMINER INITIAL				DOCUMENT NUMBER		DATE		NAME		CLASS		SUBCLASS		FILING DATE IF APPROPRIATE									
		CA																					
FOREIGN PATENT DOCUMENTS																							
				DOCUMENT NUMBER		DATE		COUNTRY		CLASS		SUBCLASS		TRANSLATION YES NO									
		CB																					
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)																							
/RL/ 		CC		J. Dancey et al., "Issues and Progress with Protein Kinase Inhibitors for Cancer Treatment", Nature Rev. Drug Discovery, Vol. 2, pp. 296-313, April 2003.																			
		CD		Y. Yarden et al., "Untangling the ErbB signalling network", Nature Rev. Molecular Cell Biology, Vol. 2, pp. 127-137, February 2001.																			
		CE		J. Baselga et al., "Why the epidermal growth factor receptor? The rationale for cancer therapy", The Oncologist, Vol. 7, Suppl. 4, pp. 2-8, 2002.																			
		CF		R. S. Herbst et al., "Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: Results of a Phase I trial", Journal of Clinical Oncology, Vol. 20, No. 18, pp. 3815-3825, September 15, 2002.																			
		CG		Ch. Dittich et al., "Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration", European Journal of Cancer, Vol. 38, pp. 1072-1080, 2002.																			
		CH		J. Mendelsohn et al., "Status of epidermal growth factor receptor antagonist in the biology and treatment of cancer", Journal of Clinical Oncology, Vol. 21, No. 14, pp. 2787-2799, July 15, 2003.																			
		CI		C. Meyer zum Buschenfelde et al., "The generation of both T killer and Th cell clones specific for the tumor-associated antigen HER2 using retrovirally transduced dendritic cells", The Journal of Immunology, Vol. 167, pp. 1712-1719, 2001.																			
		CJ		D. K. Moscatello et al., "A naturally occurring mutant human epidermal growth factor receptor as a target for peptide vaccine immunotherapy of tumors", Cancer Research, Vol. 57, pp. 1419-1424, April 15, 1997.																			
		CK		A. Ullrich et al., "Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells", Nature, Vol. 309, pp. 418-425, May 31, 1984.																			
		CL		A. T. Baron et al., "Monoclonal antibodies specific for peptide epitopes of the epidermal growth factor receptor's extracellular domain", Hybridoma, Vol. 16, No. 3, pp. 259-271, 1997.																			
		CM		H. Shomura et al., "Identification of epidermal growth factor receptor-derived peptides recognised by both cellular and humoral immune responses in HLA-A24* non-small cell lung cancer patients", European Journal of Cancer, Vol. 40, pp. 1776-1786, 2004.																			
EXAMINER								/Robert Landsman/								DATE CONSIDERED				11/15/2008			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.